Clinical Trial News and Research

RSS

Lancet issues correction on paper than prompted WHO to suspend Hydroxychloroquine trial

The World Health Organization (WHO) suspended the hydroxychloroquine trial amid the coronavirus pandemic. The decision comes after the study findings published in The Lancet reported issues on the drug's efficacy and safety. Now, the journal has issued a correction on the figures reported in the study.

2 Jun 2020

Blood test may predict a patient’s response to prostate cancer treatment

A team of researchers at The Institute of Cancer Research (ICR) in London found that the test can detect traces of cancer DNA in the bloodstream. The liquid biopsy could also identify the patients who are more likely to relapse.

1 Jun 2020

Crucial ingredient from University of Kansas included in authorized COVID-19 drug

When the Food and Drug Administration issued an emergency-use authorization for the investigational pharmaceutical remdesivir to treat COVID-19 on May 1, in part it was due to pioneering work performed by pharmaceutical chemists at the University of Kansas School of Pharmacy in 1990.

1 Jun 2020

Update on PALLAS triaI evaluating adjuvant palbociclib for early breast cancer

The Austrian Breast & Colorectal Cancer Study Group, Alliance Foundation Trials, the Breast International Group, PrECOG, LLC, the German Breast Group, and the NSABP Foundation today announced that the independent Data Monitoring Committee for the global Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study trial determined that the study is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival following a preplanned interim analysis.

1 Jun 2020

Reducing inflammation improves stroke recovery, may extend window for therapy

Reperfusion therapy, the gold standard for stroke treatment, helps restore blood flow after a stroke caused by a clot, preventing loss of brain tissue. However, only about 10% of stroke patients qualify, in part because of reperfusion therapy's narrow treatment window.

1 Jun 2020

Study could make genetic testing more accessible to women

Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who might have a genetic risk often don't get tested.

1 Jun 2020

Researchers use optical mapping system to observe the effect of hydroxychloroquine

The malaria drug hydroxychloroquine, which has been promoted as a potential treatment for Covid-19, is known to have potentially serious effects on heart rhythms.

1 Jun 2020

Ruxolitinib shows promise in severe COVID-19

An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial,” was published as a pre-proof for the Journal of Allergy and Clinical Immunology.

31 May 2020

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival (PFS) outcomes for women with platinum-sensitive ovarian cancer; however, activity between the treatments was similar in patients.

30 May 2020

New immunotherapy for metastatic non-small cell lung cancer shows promise in clinical trial

A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System.

30 May 2020

Immunotherapy doubles progression-free survival time of patients with advanced bowel cancer

A large international trial involving UCL and University College London Hospitals NHS Foundation Trust (UCLH) has found that pembrolizumab, a form of immunotherapy, more than doubled the 'progression free survival' time of patients with a specific subtype of advanced bowel cancer, when compared with chemotherapy.

30 May 2020

Developing an international consortium to improve clinical decision-making in Hodgkin lymphoma

A harmonization of 'big data' in examining long-term outcomes with contemporary treatment for pediatric and adult Hodgkin lymphoma patients is yielding a new approach to inform future clinical trial design and enhance clinical decision-making.

30 May 2020

Preventing novel coronavirus from entering into a host cell

How might the novel coronavirus be prevented from entering a host cell in an effort to thwart infection? A team of biomedical scientists has made a discovery that points to a solution.

30 May 2020

Clinical trial shows anti-tumor responses in metastatic castration-resistant prostate cancer patients

The preliminary results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC protein degrader, demonstrates clinical evidence of anti-tumor responses in patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior therapy.

29 May 2020

C-DOCTOR receives $30-million grant from NIDCR for tissue and organ regeneration research

The initiative aims to propel USC forward as the epicenter of tissue and organ regeneration research.

29 May 2020

Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS

The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43.

29 May 2020

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma.

29 May 2020

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer's disease finds that it is safe and well-tolerated, and researchers say the drug should be tested in a larger study to further determine its safety and efficacy as a potential disease-modifying strategy.

29 May 2020

Researchers test new treatment protocol for lymphoma

Lymphoma is a type of blood cancer that develops from lymphocytes (a type of white blood cell). It has many subtypes.

29 May 2020

Clinical Trial News and Research

Lancet issues correction on paper than prompted WHO to suspend Hydroxychloroquine trial

Blood test may predict a patient’s response to prostate cancer treatment

Crucial ingredient from University of Kansas included in authorized COVID-19 drug

Update on PALLAS triaI evaluating adjuvant palbociclib for early breast cancer

Reducing inflammation improves stroke recovery, may extend window for therapy

Study could make genetic testing more accessible to women

Researchers use optical mapping system to observe the effect of hydroxychloroquine

Ruxolitinib shows promise in severe COVID-19

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

New immunotherapy for metastatic non-small cell lung cancer shows promise in clinical trial

Immunotherapy doubles progression-free survival time of patients with advanced bowel cancer

Developing an international consortium to improve clinical decision-making in Hodgkin lymphoma

Preventing novel coronavirus from entering into a host cell

Clinical trial shows anti-tumor responses in metastatic castration-resistant prostate cancer patients

C-DOCTOR receives $30-million grant from NIDCR for tissue and organ regeneration research

Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

Researchers test new treatment protocol for lymphoma

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer